Aldeyra Therapeutics Inc (NASDAQ: ALDX) is one of those biotech companies you love to hate. They don’t have any revenue and in a constant development. That means that they need a constant infusion of capital to survive. The company is primarily working on treatments for diseases with a high level of aldehydes. Two of the most common diseases associated with high levels of aldehydes is Alzheimer’s and Parkinson’s disease.
Investors are always weighing the potential of companies like ALDX to develop a breakthrough treatment. This is where the funding comes in. The company announced the placement of 4,580,361 shares of common stock with Perceptive Advisors, LLC and Avidity Partners Management LP. Perceptive ended up taking down 3.2 million of the offering at $4.25. That addition over doubled their shares from just over 3 million to 6.285 million.
The news led to a 21.28% move on Tuesday as the stock price broke through the July 10 and the June 1 highs.
- This Leaked Wall Street Calendar Is Tipping of Repeat Gains
Multi-millionaire Florida hedge fund manager has just released a secret Wall Street calendar that he’s been using to land massive gains on the same stocks on the same dates for an entire decade.
And just by looking at his recent trades…. There’s no signs of this “repeat phenomenon” slowing down…
168.09% on SHW… 60.0% on ATVI… 168.97% on SMG… and TEN others just in the last few months… all going up on the same dates, every year, for an entire decade.
Here are links to our latest insider trading reports.
Action to Take: Tuesday’s breakout led the price to break through the 61.8% Fibonacci retracement of the downtrend from December 26, 2019 to the March low. The indication would be a full retracement back to the December high near $7.